Geron Corporation (NASDAQ:GERN) Q2 2023 Results Earnings Conference Call August 3, 2023 4:30 PM ET

Company Participants

Aron Feingold - Vice President, Investor Relations and Corporate Communications

John Scarlett - Chairman of the Board, President and Chief Executive Officer

Faye Feller - Executive Vice President and Chief Medical Officer

Anil Kapur - Executive Vice President, Corporate Strategy and Chief Commercial Officer

Olivia Bloom - Executive Vice President, Finance, Chief Financial Officer and Treasurer

Conference Call Participants

Kalpit Patel - B. Riley Securities

Sam Ravina - Wedbush Securities

Corinne Jenkins - Goldman Sachs

Gil Blum - Needham & Company

Joel Beatty - Robert W. Baird & Co.

Operator

Good afternoon, everyone. Welcome to the Geron Corporation Second Quarter 2023 Earnings Conference Call. I am Aron Feingold, Geron's Vice President of Investor Relations and Corporate Communications.

I'm joined today by several members of Geron's management team: Dr. John Scarlett, Chairman and Chief Executive Officer; Olivia Bloom, Executive Vice President and Chief Financial Officer; Dr. Faye Feller, Executive Vice President and Chief Medical Officer; Anil Kapur, Executive Vice President of Corporate Strategy and Chief Commercial Officer; Dr Andrew Grethlein, Executive Vice President and Chief Operating Officer.

Before we begin, please note that, during the course of this presentation and question-and-answer session, we will be making forward-looking statements regarding future events, performance, plans, expectations and other projections including those relating to the therapeutic potential and potential regulatory approval of imetelstat, anticipated clinical and commercial events and related time lines, the sufficiency of Geron's financial resources and other statements that are not historical facts. Actual events or results could differ materially. Therefore, I refer you to the discussion under the heading Risk Factors in Geron's quarterly report on Form 10-Q for the quarter ended June 30, 2023, which identifies important factors that could cause actual results to differ materially from those contained in the forward-looking statements. Geron undertakes no duty or obligation to update our forward-looking statements.

With that, I will turn the call over to Chip. Chip?

John Scarlett

Thanks, Aaron. Good afternoon, everyone. Thanks for joining us today. Geron's most recent quarter was punctuated by important achievements, which support our evolution from a late stage clinical development company toward one with future substantial commercial capabilities.

Foremost among these achievements was the submission in mid-June of a New Drug Application for imetelstat in lower risk MDS. This was the first NDA ever submitted for telomerase inhibitor and reflects our team's dedication, commitment and focus on groundbreaking and innovative drug development over many years.